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Background/Aims: Carnitine and vitamin complex (GodexⓇ) is widely used in patients with chronic liver disease who 
show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine 
from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients. 
Methods: 130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to 
the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level 
after 12 months. 
Results: Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 
58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 
85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL 
at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was.
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INTRODUCTION 
Chronic Hepatitis B (CHB) is a leading cause of liver cirrhosis 
and hepatocellular cacinoma in South Korea and a disease that af-
fects over 3 billion people worldwide. Recently, a significant im-
provement has been made in the treatment of CHB, as various an-
tiviral agents were developed. According to the 3-phase clinical 
research that compared the effects of lamivudine in HBeAg-posi-
tive CHB for 12 months, Entecavir was superior to lamivudine in 
the aspects of a decrease of serum HBV DNA, the rate of unde-
tectable HBV DNA (less than 300 copies/mL) and alanine amino-
transferase (ALT) normalization rate.1 The effect of hepatitis B an-
tiviral drugs has been greatly enhanced thanks to the recent 
development of entecavir, but the non-response rate of serum ALT 
level even after 12-month treatment and the rate of partial viro-
logic response were reported 20-30%.2 
GodexⓇ which is carnitine and vitamin complex has been used 
in patients with various liver disease to reduce liver enzyme level. 
Among previous studies, one clinical test of carnitine complex re-
ported that the ALT normalization rate of ALT elevated chronic liv-
er disease with carnitine complex was 86%.3 Carnitine has 
showed beneficial effects on various liver disease. The counteract-
ing effect of carnitine on alcoholic fatty liver disease is well docu-
mented.4 Dietary supplementation with L-carnitine significantly re-
duced steatosis, mild inflammation, elevated plasma alanine 
aminotransferase and tumor necrosis factor alpha.5 However, the 
exact mechanism by which carnitine reduces steatosis is not clear. 
Elliott et al suggested that one mechanism may involve Kupffer 
cells, the resident liver macrophages.6 Carnitine and its acyl deriv-
atives can modulate eicosanoid synthesis by peritoneal macro-
phages, and decrease their response to chemotactic stimuli.6 Car-
nitine and vitamin complex supplement reduced serum ALT, 
aspirate aminotransferase (AST), and bilirubin in nonalcoholic fatty 
liver disease.4 Carnitine transports long chain fatty acid to mito-
chondria and cause beta-oxidation, which helps to reduce intrahe-
patic fat mass and inflammation of non-alcoholic fatty liver dis-
ease.7-8 Moreover, the co-administration of carnitine to patients 
with chronic hepatitis C is reported not only to reduce symptoms, 
but also to lower the frequency of hematological abnormality re-
sulted from interferon treatment.9-11 It is known that the adminis-
tration of carnitine influences the activation of lymphocyte.12 Also, 
carnitine regulates the production of prostaglandin E1 and E2 to 
control the functions of lymphocyte.12 Carnitine has diverse effects 
on various liver disease via fatty acid oxidation, immune modula-
tion, and mitochondrial biosynthesis, etc.4-6 However, effects of 
supplementary carnitinine on CHB have been not investigated. 
The purpose of this study is to assess the effect of improving 
the liver inflammation when GodexⓇ is co-administered to ALT el-
evated CHB patients who go through the antiviral drug therapy 
and to identify the clinical safety of carnitine complex.
PATIENTS AND METHODS
Subjects
The subjects of this study are hepatitis patients whose ALT is 
greater than or equal to 80 U/L but the ALT is less than or equal to 
10 times the upper limit of normals and who did not receive the 
antiviral drug therapy. Specifically, HBV >105 copies/mL in case of 
HBeAg positive and HBV >104 copies/mL in case of HBeAg nega-
tive were included in this study. Acute hepatitis A patients and 
chronic hepatitis C patients were excluded. Among liver cirrhosis 
patients, those who had hepatic coma, esophageal variceal hem-
orrhage, spontaneous bacterial peritonitis, and uncompensated 
liver cirrhosis of Child-Pugh score ≥10 were excluded. Also, pa-
tients with hepatocellular carcinoma and malignant tumors in oth-
er organs, patients with creatinine of greater than 1.5 times ULN, 
patients given immunosuppressive drugs in 6 months prior to the 
enrollment in this study, and patients with serious diseases be-
Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT 
value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-
treatment. 
Conclusions: ALT normalization rate was higher in carnitine complex combination group than entecavir group in 
CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA 
normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment. (Clin Mol Hepatol 
2013;19:165-172)
Keywords: Hepatitis B; Carnitine; Entecavir 
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lieved to affect the test other than liver disease (e.g. uncontrolla-
ble diabetes, alcoholics, and malignant tumor, etc.) were excluded.
Stratified randomization
Subjects are randomized at an one to one ratio to the entecavir 
monotherapy and the entecavir plus carnitine complex (GodexⓇ, 
Seoul, Celltrion pharm) combination therapy. After the central in-
stitution grants randomized groups to the study organization, ran-
domization is carried out by stratifying the groups according to 
the presence of HBeAg by checking if they were HBeAg positive or 
negative at the time of screening. Computer program generates a 
list of random numbers. First, with the date of random number 
generation set as a seed number, two random numbers are creat-
ed and then used as seed numbers for creating random numbers 
for two HBeAg positive and negative groups. The block sizes of 
four and six are both used. Sufficient random numbers are gener-
ated in each layer. In each block, entecavier plus carnitine complex 
combination therapy (test group) was allocated with small num-
bers and entecavir monotherapy (control group) was allocated to 
big numbers depending to the size of random numbers. The ran-
domization table is randomly allocated to subjects depending on 
HBeAg type in the order of the subject patients’ enrollment in the 
study organization. They are randomly selected to be divided into 
a monotherapy group and a combination therapy group. Entecavir 
(0.5 mg) and entecavir plus carnitine complex (2 cap./time, 3 
times/day, totally 2,472 mg/day, oral administration) were given to 
the monotherapy group and the combination therapy group, re-
spectively for 12 months.
Test items & schedule
Before and 3, 6, 9, 12 months after medication, ALT, AST, biliru-
bin, HBV-DNA PCR, HBsAg, HBsAb, HBeAg, and HBeAb were 
measured. Then abdominal ultrasonography and AFP examination 
were carried out every six months. HBV DNA was measured by re-
al-time PCR method on a central lab using a COBAS TaqMan anal-
yser (Roche Diagnostics, Mannheim, Germany) with a detection 
limit of 20 IU/mL. Quantitative HBsAg was tested on a central lab 
using the ARCHITECT HBsAg QT immunoassay (Abbott Diagnos-
tics, Wiesbaden, Germany). Quantitative HBsAg was examined ev-
ery 3 months during the follow-up period.
Lymphocyte interferon-γ secretion test
Interferon gamma enzyme-linked immunosorbent spot (ELISPOT) 
examination was performed using the ELISPOT test to evaluate the 
ability of leucocytic interferon-γ secretion caused by HBsAg stimu-
lation. Blood specimen was transferred to the central laboratory 
within 2 days after blood-collecting. Peripheral blood mononucle-
ar cells (PBMC) were separated here to be stored in a nitrogen 
tank. Seed 100 μL of cell suspension in 5-well plates and put 1uL 
of dilution of core and surface protein 1 to medium 9. For a posi-
tive control group, mAb CD3-2 was added until its maximum con-
centration reached 100 ng/mL and cultured in 5% CO2 incubator 
at 37℃ for 12-48 hours. The cell suspension was removed and 
washed five times using PBS. The detection reagent (mAb 7-B6-1) 
was added in the ratio of 200 to 1 in PBS where 10% FBS is con-
tained and another 100 μL of it was added into each well. Incu-
bate it at room temperature for 2 hours and wash five time using 
PBS. Filter it at 0.45 μm and put 100 μL of substrate solution 
(BCIP/NBT-plus) to be developed for 15 minutes. Water-wash and 
dry it at room temperature to be counted using ELISpot reader 
(AELVIS, Germany). 
Peripheral blood mitochondria copy number
We collected 5 mL of peripheral venous blood before and after 
administration of each drug an put it in EDTA tube to be kept in a 
freezer at -80°C. Process it in a centrifuge at room temperature 
and extract DNA from it, then measure peripheral blood mito-
chondria DNA using real-time polymerase chain reaction (PCR) us-
ing COBAS Ampliprep (Roche, Indianapolis, IN, USA). Develop a 
probe for GAPDH and mtDNA and mark 5’ terminal and 3’ termi-
nal each with 5-carboxyfluorescein(FAM) reporter and 6-carboxy-
tetramethyl-rhodamine (TAMRA) quencher. PCR was performed 
for mtDNA and PCR mixture was 15 μL which consists of TaqMan 
Universal PCR Master Mix (ABI, USA) 7.5 μL, primer forward (5 
pmol/mL) 1.5 μL, primer reverse (5 pmol/mL) 1.5 μL, probe (1 
pmol/μL) 1.5 μL, and distilled water 0.5 μL, DNA 2.5 μL. PCR used 
ABI 7500 Real-Time PCR System and amplification was repeated 
forty times on conditions of 2 minutes at 50°C, once for 10 min-
utes, 15 seconds at 95°, and 1 minute at 60°. For a qualitative 
analysis of mitochondrial DNA copy number, the comparative 
analysis using the amplification of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was implemented.
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Statistical analysis method
Since the primary end point is ALT normalization rate when 
12-month treatment is completed, Fisher’s exact test or Chi-square 
test needs to be used to verify the difference between two groups. 
But, if there are significant differences between demographic data 
and clinical history data, logistic regression analysis is used for 
correction. 
Continuous variables (HBsAg titer, HBV DNA titer, ELISPOT and 
the peripheral blood mitochondrial DNA copy number) were ana-
lyzed by t -test or Wilcoxon Rank test. Categorical variables (rate 
of ALT normalization and HBV DNA <300 copies/mL) were ana-
lyzed by the Fisher’s exact test of Chi-square test.
RESULTS
Subjects
A total of 130 patients were randomized in this clinical trial. Out 
of those randomized patients, six were excluded from analysis due 
to withdrawal, two due to follow-up failure, one due to adverse 
reactions, and two due to inclusion/exclusion criteria, while a total 
of 119 patients were included in this study (Fig. 1). The average 
ages of the monotherapy group and the combination therapy 
group were 44.9 and 43.0 years old, respectively. There was no 
difference in ALT, AST, and virus concentration in serum between 
two groups (Table 1).
Normalization rate of aminotransferase activity
Normalization rates of subjects’ serum ALT were 58.9% and 
87.5% in 3-month dosing and 6-month dosing for the monothera-
py group, and 95.2% and 100% for the combination therapy 
group, which showed that the figure was statistically higher in the 
combination therapy group (P<0.0001 vs. P =0.0038). After 
9-month dosing, the figures showed no significant difference be-
tween the monotherapy group and the combination therapy group 
(P=0.1011). At the time of 12-month dosing, the figures showed 
statistically significant difference between two groups with 85.7% 
and 100% (P=0.0019) (Fig. 2). On condition of the ALT threshold 
value below than 30 U/L for males and 19 U/L for females, the se-
rum ALT normalization rates after 3, 6, 9-month dosing were sta-
tistically significantly higher in the combination therapy. At the 
time of 12-month dosing when the study is completed, the nor-
malization rates were 69.6% in the monotherapy group and 
93.7% in the combination therapy group, which showed statisti-
cally significant difference between two groups (P=0.0006) (Table 
2). At the time of 12-month dosing, the average values of serum 
ALT were 25.2±15.0 in the monotherapy group and 13.6±5.1 in 
Table 1. Basic characteristics
Mono-therapy (n=56) Combination-therapy (n=63) P-value*
Age (yr) 44.9±10.0 43.0±9.8 0.289
Sex (M:F) 37:19 40:23 0.769
HBeAg positive 49 54 0.776
HBV-DNA PCR (108 copies/mL) 3.5±3.9 3.5±4.2 0.978
ALT (U/L) 160.3±74.9 159.4±67.5 0.944
AST (U/L) 111.3±70.2 118.8±70.3 0.565
Bilirubin (mg/dL) 0.98±0.39 0.89±0.31 0.140
Albumin (mg/dL) 4.22±0.37 4.18±0.41 0.636
Prothrombine time (INR) 1.05±0.1 1.42±2.05 0.149
*P<0.05 by chi square test and student t test.
ALT, alanine trasnsaminase; AST, aspartate aminotransferase; INR, international normalized ratio.
Figure 1. CONSORT flow chart.
Screening
n=135
Combination
therapy group
(n=63)
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Mono-therapy
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Consent withdrawal [3]
Follow up loss [2]
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the combination therapy group, which showed lower in the com-
bination therapy group (P<0.0001). When pretreatment ALT was 
over 200 U/L, the serum ALT normalization rates after 3-month 
dosing were 53.9% and 88.2% in the monotherapy group and the 
combination therapy group, respectively (P=0.0348). At the time 
of 12-month dosing when the study is completed, the ALT normal-
ization rates were 69.2% and 100% in the monotherapy group 
and the combination therapy group, respectively, which showed 
statistically significant difference between two groups (P=0.014). 
Normalization rates of subjects’ serum AST were 73.2% and 
79.4% in 3-month dosing and 12-month dosing for the monother-
apy group, and 92.6% and 88.9% for the combination therapy 
group, which showed no significant difference between the mono-
therapy group and the combination therapy group.
Seroconversion rate and virus negative conver-
sion rate
The rates of ALT normalization and HBV DNA of less than 300 
copies/mL after 3, 6, 9, 12-month dosing were 43.6%, 50.9%, 
69.1%, 75.9% in the monotherapy group and 54.8%, 50.0%, 
64.4%, 70.7% in the combination therapy group, respectively, 
which showed the increasing trend of serum virus negative con-
version rate in both groups according to treatment period, but no 
difference in HBV DNA negative conversion rate between two 
groups.
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Figure 2. ALT normalization rate during follow up period. Serum ALT 
normalization rates after 3, 6, 9-month dosing were statistically 
significantly higher in the combination therapy group than mono-
therapy group. ALT, alanine aminotransferase activity.
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tion were 14.3% and 5.6% in the monotherapy group and the 
combination therapy group, respectively while HBeAg seroconver-
sion rates were 10.2% and 5.6% in the monotherapy group and 
the combination therapy group, respectively, which showed no 
difference between two groups. In the monotherapy group, quan-
titative HBsAg level declined from 42,810 IU/mL to 10,433 IU/mL 
at the time of 12-month dosing on average, while in the combina-
tion therapy group, quantitative HBsAg level reduced from 44,037 
IU/mL to 8,621 IU/mL at the time of 12-month dosing on average, 
which showed no difference between two groups.
Lymphocyte interferon-γ secretion test 
(ELISPOT test)
Before treatment, the abilities of leucocytic interferon-γ secre-
tion caused by hepatitis B surface antigen stimulation were 56.5 
SFC/106 PBMCs and 50.5 SFC/106 PBMCs in the monotherapy 
group and the combination therapy group, respectively. But after 
12-month treatment, the ELISPOT values increased to 81.3 SFC/106 
PBMCs and 99.2 SFC/106 PBMCs, respectively. The monotherapy 
group showed no statistical difference in the ability of leucocytic 
interferon-γ secretion between pretreatment and 12-month treat-
ment (P=0.131), but the combination therapy group showed a sig-
nificant increase in the 12-month treatment compared to pretreat-
ment (P=0.030) (Fig. 3).
Peripheral blood mitochondria copy number
At the baseline and end of treatment, peripheral blood mito-
chondria copy numbers were 1,298.3 copies/mL and 2,944.1 cop-
ies/mL in the monotherapy group and 1,437.2 copies/mL and 
2,320.8 copies/mL in the combination therapy group, respectively, 
but no statistical signif icance was found in both groups 
(P=0.7351). 
Results of safety analysis
The most frequently reported adverse effects occurred during 
the study period were fatigue, skin rash, and indigestion. During 
12-months, the numbers of adverse events in monotherapy group 
and combination therapy group were 22 and 35, respectively. 
Among them only six cases were highly suggested having causal 
relationship with medication. Indigestion, skin rash, and drowsi-
ness were the frequent adverse events of the medication. Howev-
er, the prevalence of each symptom was not statistically significant 
(Table 3). Rest of symptoms did not seem to have causal relation 
Figure 3.  Changes of inter feron-γ during treatment period. 
Lymphocyte interferon-γ secretion activity was increase in both 
combination and mono-therapy group. Combination therapy group 
showed a significant increase in the 12-month treatment compared to 
pretreatment.
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Table 3. Adverse effects
Symptoms
Number of cases
P‐value*
Mono‐therapy (63) Combination‐therapy (67) Total (130)
Adverse effect 22 35 57 0.0467
Relationship possible
  ‐ Drowsiness 1 0 1 0.3006
  ‐ Skin rash 0 2 2 0.1670
  ‐ Indigestion 1 2 3 0.5958
Not related† 20 31 51 0.0901
Severe adverse effect 6 3 9 0.2573
*P<0.05 by chi square.
†Fatigue, general weakness, chronic gastritis, upper respiratory infection, and so on.
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with medication. The prevalence of fatigue, general weakness, 
chronic gastritis, and upper respiratory infection, has not related 
with treatment (P=0.2573).
DISCUSSION
In this study, the ALT normalization rate of GodexⓇ and enteca-
vir co-administration was significantly higher than those of mono-
therapy group at the time of 3, 6, 12 months after treatment. 
The normalization rate of serum ALT level was higher and the 
average value of serum ALT was lower in the combination therapy 
group of CHB patients. Mean ALT level of 12-month were 
25.1±15.0 in the monotherapy group and 13.6±5.1 in the combi-
nation therapy group, which showed the significant difference be-
tween two groups (P<0.0001). Such difference was more evident 
when the ALT level was higher at the point of the commencement 
of treatment. In this study, the ALT normalization rate at the time 
of 12-month dosing was high at 85.7% even in the entecavir 
monotherapy group which is the result similar to those of existing 
studies. However, if the ALT level was over 200 U/L at the time of 
treatment, the ALT normalization rate during the monotherapy 
was low at 53.9% and 69.2% at the time of 3-month and 
12-month treatment, respectively. On the other hand, if the ALT 
level was over 200 IU/L before treatment, the ALT normalization 
rate during the combination therapy group was significantly high 
at 88.2% and 100% at the time of 3-month and 12-month treat-
ment, respectively. Our study showed ALT normalization rate was 
nearly 100% at 6 months. That means that at six month combina-
tion treatment will have beneficial effects in case of high ALT pa-
tients. 
It is known that the administration of carnitine influences the 
activation of lymphocyte.12 Carnitine regulates the production of 
prostaglandin E1 and E2 to control the functions of lymphocyte.12 
Hao et al also reported that a diet containing carnitine improved 
the functions of lymphocyte of type II diabetic patients.13-14 This 
study was aimed to identify the effects of GodexⓇ co-administra-
tion on an immune reaction. It is known that if the virus concen-
tration of CHB patients is high, the ‘anergy’ occurs that slows 
down the T-cell function.15 In this study, patients’ lymphocyte was 
stimulated using hepatitis B virus surface antigen in order to eval-
uate the T-cell’s function. Amount of lymphocyte interferon-γ se-
cretion was not different between two groups at the end of 12 
months. However, interferon-γ secretion was significantly in-
creased only in combination group comparing to baseline 
(P=0.030). Such results were consistent with those of preceding 
studies which reported that the administration of GodexⓇ includ-
ing carnitine affected the regulation of an immune reaction. How-
ever, HBeAg seroclearance and seroconversion rate after 12-month 
treatment showed no statistical difference between the mono-
therapy group and combination therapy group. The reason of dis-
crepancy between changes of INF-γ secretion and seroclearance 
rate is not clear. These mean that immune reaction shows no sta-
tistical significance between two groups. Significant INF-γ secre-
tion increase was shown in mono-therapy arm within-group com-
parison, but INF-γ secretion was not different between two arms 
at the end of study. Other researches on Godex’s potential to reg-
ulate the immune reaction also reported that biphenyl dimethyl di-
carboxylate (DDB) containing GodexⓇ suppressed the reproduc-
tion and activation of hepatitis B virus by stimulating the 
interferon alpha route.16 But according to this study, there was no 
difference in the virus concentration in serum between the mono-
therapy group and combination group.
In conclusion, co-treatment of entecavir and GodexⓇ to CHB 
patients can improve the ALT normalization rate, and especially 
when the ALT level was over 200 U/L before treatment, the nor-
malization rate of liver inflammation level was higher.
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